{"id":"brand-lamotrigine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"10-20","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL741","moleculeType":"Small molecule","molecularWeight":"256.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:05.790Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive and monotherapy)"},{"name":"Bipolar I disorder maintenance treatment"},{"name":"Lennox-Gastaut syndrome"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT01995825","phase":"PHASE4","title":"Lamotrigine Bioequivalence","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02821338","phase":"PHASE1","title":"A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2016-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT02404168","phase":"PHASE4","title":"BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-07-07","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT01733394","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-12-12","conditions":"Epilepsy","enrollment":54},{"nctId":"NCT01713777","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-04","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Brand lamotrigine","genericName":"Brand lamotrigine","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive and monotherapy), Bipolar I disorder maintenance treatment, Lennox-Gastaut syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}